flipper tr lipid membrane tension probe Search Results


90
Dojindo Labs lipid peroxidation probe bodipy-c11 581/591
Lipid Peroxidation Probe Bodipy C11 581/591, supplied by Dojindo Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipid peroxidation probe bodipy-c11 581/591/product/Dojindo Labs
Average 90 stars, based on 1 article reviews
lipid peroxidation probe bodipy-c11 581/591 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher bodipy lipid probe d3861
Bodipy Lipid Probe D3861, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bodipy lipid probe d3861/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
bodipy lipid probe d3861 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher vybrant lipid raft labeling kit
Vybrant Lipid Raft Labeling Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vybrant lipid raft labeling kit/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
vybrant lipid raft labeling kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher bodipy fl lipids
Bodipy Fl Lipids, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bodipy fl lipids/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
bodipy fl lipids - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

86
Thermo Fisher hcs lipidtox red neutral lipid stain
Hcs Lipidtox Red Neutral Lipid Stain, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hcs lipidtox red neutral lipid stain/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
hcs lipidtox red neutral lipid stain - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier

90
Thermo Fisher vybrant lipid rafts labeling kit
Vybrant Lipid Rafts Labeling Kit, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/vybrant lipid rafts labeling kit/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
vybrant lipid rafts labeling kit - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher lipidtox green neutral lipid stain
Lipidtox Green Neutral Lipid Stain, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lipidtox green neutral lipid stain/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
lipidtox green neutral lipid stain - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher bodipy–ceramide
Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe <t>bodipy‐ceramide</t> as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)
Bodipy–Ceramide, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bodipy–ceramide/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
bodipy–ceramide - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher 1,10-dioctadecyl-3,3,30,30tetramethylindocarbocyanine perchlorate (dii
Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe <t>bodipy‐ceramide</t> as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)
1,10 Dioctadecyl 3,3,30,30tetramethylindocarbocyanine Perchlorate (Dii, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/1,10-dioctadecyl-3,3,30,30tetramethylindocarbocyanine perchlorate (dii/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
1,10-dioctadecyl-3,3,30,30tetramethylindocarbocyanine perchlorate (dii - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher fm 4–64
Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe <t>bodipy‐ceramide</t> as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)
Fm 4–64, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fm 4–64/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
fm 4–64 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher bodipy 505/515 staining
Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe <t>bodipy‐ceramide</t> as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)
Bodipy 505/515 Staining, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bodipy 505/515 staining/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
bodipy 505/515 staining - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Thermo Fisher bodipy 493/503
Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe <t>bodipy‐ceramide</t> as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)
Bodipy 493/503, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bodipy 493/503/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
bodipy 493/503 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe bodipy‐ceramide as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)

Journal: Journal of Extracellular Vesicles

Article Title: Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome‐enriched vesicles

doi: 10.1002/jev2.12211

Figure Lengend Snippet: Characterization of sEV secreted from control‐ or DDA‐treated B16F10 cells. Analysis of sEV isolated from the culture media of B16F10 cells treated with the solvent vehicle (C‐sEV) or DDA (DDA‐sEV) for 24 h. (a) Representative flow cytometry analysis of sEV tetraspanin content ( n = 3). (b) Representative immunoblot analysis of markers of sEV (Alix, Tsg101, Flotilin (Flo), LC3 II, Annexin A1 (AnxA1) and the melanocytic marker tyrosinase (Tyr) ( n = 3) with densitometry values showing changes in protein expression relative to C‐sEV and normalized to Alix. (c) Representative flow cytometry analysis of sEV calreticulin content ( n = 5). (d) GC/MS analysis of cholesterol content in sEV ( n = 3). (e) Representative flow cytometry analysis of BMP quantification in sEV ( n = 5). (f) Immunocapture of CD63‐positive sEV with an anti‐CD63 antibody fixed to beads and analysis of the presence of BMP in CD63‐positive sEV by flow cytometry analysis ( n = 4). Data is expressed as percentage of positive beads and are the mean ± SEM of four independent experiments (* P < 0.05, t test, two‐tailed). (g) Quantification of sEV production from B16F10 cells, treated with increasing concentrations of DDA, monitored after sEV labelling with the lipid membrane probe bodipy‐ceramide as described in the schematic diagram, ( n = 3). (h) sEV production recovered from 10 6 cells was measured by measuring protein content ( n = 5). (i) Mice (15/group) were implanted with B16F10 tumour cells in the right flank and treated two times, at day 0 and day 7, in the contralateral flank with PBS or with 2 μg of C‐sEV or DDA‐sEV. Mean tumour volumes (± SEM) are shown, two‐way ANOVA, ** P < 0.01, **** P < 0.0001. ns: not significant. Data are representative of three independent experiments. The plots in (c) and (e) show the median fluorescence intensity (MFI) of DDA‐ sEV relative to C‐sEV. Data in c, d, e, g, h are the means ± SEM of 3–5 independent experiments (* P < 0.05 and ** P < 0.01, t test, two‐tailed; ns: not significant)

Article Snippet: The fluorescent lipid probe Bodipy–Ceramide was from Invitrogen–Molecular Probes.

Techniques: Isolation, Flow Cytometry, Western Blot, Marker, Expressing, Gas Chromatography-Mass Spectrometry, Two Tailed Test, Fluorescence